Bill Detail
S. 832
Congress: 119
Title
EPIC Act of 2025
Summary
Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program. The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.
Sponsor
Sen. Thomas Tillis [R-NC]
Status
Read twice and referred to the Committee on Finance.
Status as of Jun 29, 3:17 PM · synced 5h ago
Introduced
2025-03-04
Data source mode: cache
Bill Engagement
Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 This bill lengthens the amount of time for which drug products must have market approval in order for t…
Lobbyists on the case
- Pharmaceutical Research and Manufacturers of America5 filings · 28 lobs
- Biotechnology Innovation Organization2 filings · 12 lobs
- Johnson & Johnson Services, Inc.1 filing · 16 lobs
- Crossroads Strategies, LLC1 filing · 10 lobs
- Dla Piper LLP (US)1 filing · 6 lobs
- Williams and Jensen, PLLC1 filing · 3 lobs
- Teresa Bill2026 Q1
- Elenora Connors2026 Q1
- Catherine Douglas2026 Q1
- Bart Forsyth2026 Q1
- Jake Freed2026 Q1Pharmaceutical Research and Manufacturers of America · Cong. Affairs Specialist - FDA; Leg. Asst., Leg. Aide/Press Asst., Staff Asst., District Field Re…
- Kelly Goldberg2026 Q1
- Judith Haron2026 Q1
- Lauren Jee2026 Q1